RxDoctor Payments Data

Ann Tong, MD

Cardiovascular Disease · Gainesville, FLNPI 1902879323

Payments from drug & device makers

$218,882in general payments, 2019–2025

Across 431 payments — averaging $507.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$131K
  • Novartis$49K
  • Boston Scientific$15K
  • Bayer$14K
  • Abbott$6K
  • Alnylam Pharmaceuticals Inc.$849
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$22,86314%
  • Speaking & faculty fees$111,55170%
  • Travel & lodging$16,53310%
  • Food & beverage$9,3846%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$218,882 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$729,690
Medicare patients
1,628
Services billed
6,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban364$341,328
CamzyosMavacamten38$300,602
EntrestoSacubitril/Valsartan230$225,037
JardianceEmpagliflozin269$219,274
XareltoRivaroxaban77$72,710
FarxigaDapagliflozin Propanediol75$57,299
Repatha SureclickEvolocumab67$48,672
Repatha PushtronexEvolocumab25$18,357
Praluent PenAlirocumab28$14,092
MultaqDronedarone Hcl12$12,275
VascepaIcosapent Ethyl15$8,768
Dabigatran EtexilateDabigatran Etexilate Mesylate24$7,784
Metoprolol Succinate576$7,255
VerquvoVericiguat11$7,176
CorlanorIvabradine Hcl15$5,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$343$341,328364 claims
E.r. Squibb & Sons, L.L.C.Camzyos$130,898$300,60238 claims
NovartisEntresto$48,895$225,037230 claims
Boehringer IngelheimJardiance$423$219,274269 claims
Johnson & JohnsonXarelto$152$72,71077 claims
AstraZenecaFarxiga$79$57,29975 claims
Sanofi-aventis U.S. LLCMultaq$206$12,27512 claims
MerckVerquvo$294$7,17611 claims
AmgenCorlanor$494$5,14315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →